华邦生命健康股份有限公司 股东会议事规则 （2025年4月修订稿） 第一节 总则 第一条 股东会由本公司股东组成，是公司的权力机构。为保证股东会能够依法 行使职权，根据《中华人民共和国公司法》（以下简称"《公司法》"），《中华人民 共和国证券法》、《上市公司股东会规则》（以下简称"《股东会规则》"）、《深圳 证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》、《华邦生命 健康股份有限公司章程》（以下简称"公司章程"）等相关规定，制定本规则。 第二条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定召开 股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当勤勉 尽责，确保股东会正常召开和依法行使职权。 第三条 公司股东会由全体股东组成。股东会是公司的权力机构，依法行使下列 职权： （一）选举和更换董事，决定有关董事的报酬事项； （二）审议批准董事会的报告； （三）审议批准公司的利润分配方案和弥补亏损方案； （四）对公司增加或者减少注册资本作出决议； （五）对发行公司债券作出决议； （六）对公司合并、分立、解散、清算或者变更公司形式作出决议； ...

华邦生命健康股份有限公司董事会 关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作》等要求，结合独立董事独立性自查 情况，华邦生命健康股份有限公司（以下简称"公司"）董事会对公司独立董 事黎明先生、刘忠海先生的独立性情况进行评估并出具如下专项意见： 独立董事（黎明）关于 2024 年度独立性的自查报告 经核查，独立董事黎明先生、刘忠海先生的任职经历以及提交的独立性自 查报告，其未在公司担任除独立董事以外的任何职务，也未在公司主要股东公 司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其 进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上市公 司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》等监管规则及《华邦生命健康股份有限公司章程》中 关于独立董事的任职资格及独立性的要求。 后附独立董事关于 2024 年度独立性的自查报告。 华邦生命健康股份有限公司 董 事 会 2025 年 4 月 23 日 1 华邦生命健康股份有限公司 本人黎明作为华邦生 ...

华邦生命健康股份有限公司 2024 年度独立董事试职报告 (刘忠海) 各位股东及股东代表: 作为华邦生命健康股份有限公司(以下简称"公司")的独立董事,本人在 2024 年度严格按照《公司法》、《上市公司独立董事管理办法》、《深圳证券交易 所上市公司自律监管指引第1 号 -- 主板上市公司规范运作》、《公司章程》、《独 立董事工作制度》、《独立董事专门会议工作制度》等有关规定,本着对全体股东 负责的态度,忠实地履行独立董事的职责,谨慎、认真、勤勉地行使了独立董事 的权力。积极出席公司股东大会、董事会、专门委员会,对公司重大事项发表客 观、审慎、公正的独立意见,积极维护公司整体利益和全体股东特别是中小股东 的合法权益,对公司规范、稳定、健康地发展起到了积极的推动作用。现就本人 2024 年度任职期间的履职情况汇报如下: 一、个人基本情况 作为公司的独立董事,本人具备《上市公司独立董事管理办法》所要求的独 立性,并按照监管规则进行了独立性自查,不存在影响独立性的情况。本人与公 司及其控股股东不存在可能妨碍独立客观判断的关系,不受公司控股股东或者其 他与公司存在利害关系的单位或个人的影响。 二、2024年度履职概况 ...

华邦生命健康股份有限公司 董事会议事规则 （2025 年 4 月修订稿） 第一条 为规范华邦生命健康股份有限公司（以下简称"公司"）董事会及 其成员的行为，保证公司决策行为的民主化、科学化，适应建立现代企业制度的 需要，特制订本规则。 第二条 本规则根据《中华人民共和国公司法》（以下简称"《公司法》"） 及其他现行有关法律、法规和《华邦生命健康股份有限公司章程》（以下简称"公 司章程"）制订。 第三条 公司董事会及其成员除遵守《公司法》等有关法律、法规、公司章 程外，亦应遵守中国证券监督管理委员会对上市公司董事会和董事的有关文件、 《深圳证券交易所股票上市规则》和《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》及本规则的有关规定。 董事任期从就任之日起计算，至本届董事会任期届满时为止。董事任期届满 未及时改选，在改选出的董事就任前，原董事仍应当依照法律、行政法规、部门 规章和公司章程的规定，履行董事职务。 董事可以由高级管理人员兼任，但兼任高级管理人员职务以及由职工代表担 任的董事，总计不得超过公司董事总数的 1/2。 第七条 董事会由 6 名董事组成，设董事长 1 名，副董事长 1 ...

数据四舍五入，查看更多财务数据>> 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.1514 | 0.1526 | -199.21 | 0.2189 | | 每股净资产（元） | 4.73 | 5.1 | -7.25 | 5.15 | | 每股公积金(元) | 2.68 | 2.67 | 0.37 | 2.65 | | 每股未分配利润(元) | 0.81 | 1.18 | -31.36 | 1.29 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 116.65 | 115.95 | 0.6 | 132.32 | | 净利润(亿元) | -2.99 | 3.02 | -199.01 | 4.33 | | 净资产收益率(%) | -1.85 | 2.99 | -161.87 | 4.25 | 前十大流通股东累计持有： 64001.25万股，累计占流通股比： 34.01%，较上期变化： -1 ...

Revenue and Profitability - The company's revenue for Q1 2025 was ¥2,820,969,309.75, a decrease of 3.24% compared to ¥2,915,489,646.11 in the same period last year[4] - Net profit attributable to shareholders increased by 18.50% to ¥184,340,340.89 from ¥155,559,826.48 year-on-year[4] - Basic earnings per share rose by 18.83% to ¥0.0934, compared to ¥0.0786 in the same period last year[4] - Net profit for the current period was CNY 240,798,487.12, an increase of 12.29% compared to CNY 214,428,922.38 in the previous period[14] - Earnings per share (EPS) for the current period was CNY 0.0934, up from CNY 0.0786 in the previous period[14] Cash Flow and Liquidity - The net cash flow from operating activities decreased significantly by 66.06% to ¥37,850,414.72, down from ¥111,518,296.72 in the previous year[4] - Operating cash inflow for the current period was CNY 2,295,889,085.16, an increase of 0.5% from CNY 2,276,286,581.64 in the previous period[16] - Cash inflow from investment activities increased to CNY 4,663,881,764.88, up 22.4% from CNY 3,812,855,758.89 in the previous period[16] - Net cash flow from investment activities improved to CNY 119,334,251.27, compared to a negative CNY 573,043,653.12 in the previous period[16] - Cash inflow from financing activities totaled CNY 2,026,943,005.73, a decrease of 7.6% from CNY 2,194,591,456.31 in the previous period[17] - Net cash flow from financing activities decreased to CNY 219,053,669.61, down 70% from CNY 731,469,429.37 in the previous period[17] - The net increase in cash and cash equivalents was CNY 385,971,915.90, compared to CNY 276,277,439.55 in the previous period[17] - The ending balance of cash and cash equivalents was CNY 3,037,740,916.47, down from CNY 3,104,339,719.27 in the previous period[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥29,838,585,616.20, reflecting a 1.32% increase from ¥29,450,469,334.61 at the end of the previous year[4] - Total current assets increased to CNY 11,760,657,341.32 from CNY 11,276,705,434.24, reflecting a growth of approximately 4.3%[10] - Total liabilities increased to CNY 14,114,956,018.60 from CNY 13,977,060,015.24[12] - Non-current assets totaled CNY 18,077,928,274.88, slightly down from CNY 18,173,763,900.37[12] - The company’s total equity increased to CNY 15,723,629,597.60 from CNY 15,473,409,319.37[12] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 76,797, with no preferred shareholders[8] - The largest shareholder, Tibet Huibang Technology Co., Ltd., holds 18.71% of the shares, totaling 370,449,804 shares[8] Other Income and Expenses - The company reported a significant increase in investment income, which rose by 96.64% to ¥12,700,521.39 from ¥6,458,725.60 year-on-year[6] - Other income increased by 53.42% to ¥19,541,583.62, primarily due to higher government subsidies related to daily operations[6] - The company experienced a 49.77% decrease in contract liabilities, dropping to ¥113,285,447.03 from ¥225,513,904.85 due to reduced advance payments received[6] - The company reported a decrease in research and development expenses to CNY 107,103,304.50 from CNY 94,529,223.40, reflecting a 13.38% increase[13] Financial Reporting - The company did not undergo an audit for the first quarter report[18] - The report was issued by the Board of Directors on April 23, 2025[19]

Pharmaceutical Research and Development - In 2024, the company achieved significant progress in pharmaceutical research and development, with 4 formulation products receiving market approval and 1 formulation product passing consistency evaluation[4] - Six raw material drug varieties and pharmaceutical excipients received A certification, while five raw material drug varieties obtained international certification[4] - The company launched 4 formulation products and 2 functional skincare products in 2024, enhancing its product matrix in the skin health sector[58] - The company has developed 2 new Class I drugs and over 20 generic drugs, with nearly 30 formulations passing or deemed equivalent for consistency evaluation[86] - The company has established a comprehensive data service platform to support its sales network and marketing strategies[87] - The company is expanding its product pipeline with multiple drug registration applications currently under review, including treatments for pain management and neurological diseases[115] - The company is committed to green and clean production technologies, focusing on reducing the environmental impact of its manufacturing processes[114] Financial Performance - The company's operating revenue for 2024 was CNY 11,664,669,783.79, representing a 0.60% increase compared to CNY 11,594,590,416.29 in 2023[40] - The net profit attributable to shareholders for 2024 was CNY -298,989,917.10, a significant decrease of 198.96% from CNY 302,122,026.53 in 2023[40] - The cash flow from operating activities for 2024 was CNY 1,625,292,850.24, which is a 2.25% increase from CNY 1,589,476,654.26 in 2023[40] - The total assets at the end of 2024 were CNY 29,450,469,334.61, down 4.16% from CNY 30,727,396,560.35 at the end of 2023[40] - The company's basic earnings per share for 2024 was CNY -0.1514, a decline of 199.21% from CNY 0.1526 in 2023[40] - The company reported an operating loss of CNY 12,743.50 million, a decrease of 113.75% year-on-year[98] - The company incurred non-operating losses of CNY 19,593,772.29 from the disposal of non-current assets in 2024[47] Medical Services and Operations - The medical business showed steady growth, with bed occupancy rates exceeding 90% at Beijing Huasheng Rehabilitation Hospital, indicating strong operational performance[10] - The company’s medical services, particularly at Chongqing Songshan Hospital, experienced steady growth in outpatient and surgical volumes, with bed occupancy rates exceeding 90%[59] - The company invested in the Chongqing Songshan Hospital, leading to the establishment of 16 specialized outpatient clinics, enhancing service capabilities[59] - The company aims to develop a high-quality medical service system in response to the aging population and increasing demand for healthcare services in major cities, focusing on comprehensive healthcare, rehabilitation, and cancer treatment[141] Market Expansion and Strategy - The company plans to strengthen its position in the prescription market and actively expand into the retail market to increase market share[3] - The company is actively expanding its overseas raw material drug market while consolidating its position in the prescription market domestically[58] - The company is actively expanding its retail market presence, focusing on county-level and grassroots channels, and enhancing online sales through various platforms[64] - The company aims to enhance its capacity utilization and promote CMO and CDMO projects to create additional revenue streams[137] Agricultural and New Materials Business - The agricultural and new materials businesses experienced a decline due to cyclical industry impacts, while the tourism business remained stable[14] - The agricultural chemical sector faced challenges with intensified market competition and high inventory levels, impacting overall performance[54] - The new materials segment experienced a decline in revenue and profit due to raw material price fluctuations and increased industry competition[59] - The agricultural chemical segment has a stable overseas sales revenue proportion of 49.57% for 2024, with a focus on export sales[69] Governance and Compliance - The company received an "A" rating for information disclosure from the Shenzhen Stock Exchange for the 2023-2024 period[165] - The internal audit department conducts audits on related transactions and major expenses to ensure compliance and protect shareholder rights[165] - The company emphasizes the independence of its operations from the controlling shareholders, maintaining a clear asset ownership structure and full control over its assets[167] - The company has established an independent financial management department, adhering to accounting standards and ensuring no interference from controlling shareholders in financial decisions[169] Research and Development - The company has a strong R&D team and facilities, ensuring a competitive edge in the production of chlorosulfonic acid and other fine chemical products[73] - The company has developed over 100 high-quality products in herbicides, fungicides, and insecticides, with significant market share in the domestic market[91] - The company has established a comprehensive industrial chain from basic chemical raw materials to high-performance polymer materials, positioning itself as a leading producer in its field[73] - The company is focused on developing green production technologies to recycle waste and reduce disposal costs[82] Tourism Business - The company operates three cable cars in the Yulong Snow Mountain Scenic Area and three in the Taibai Mountain National Forest Park, being the sole operator in these scenic areas[77] - The company has hotel operations in regions such as Yunnan, Chongqing, and Guangxi, including several high-end hotels like the InterContinental Resort in Lijiang[78] - The tourism service sector generated revenue of CNY 1,103,451,946.30, accounting for 9.46% of total revenue, with a year-on-year increase of 1.70%[99] Human Resources and Management - The total number of employees at the end of the reporting period was 12,572, with 61 in the parent company and 12,511 in major subsidiaries[193] - The professional composition includes 6,293 production personnel, 1,855 sales personnel, 1,965 technical personnel, 385 financial personnel, 1,614 administrative personnel, and 460 medical personnel[193] - The company has a comprehensive salary system based on "efficiency first, fairness considered, and performance highlighted," incorporating basic salary, performance bonuses, and equity incentives[194] - The training program focuses on talent development, internal collaboration, and resource sharing to enhance employee skills and efficiency[195]

华邦健康（002004）公告，2025年第一季度营业收入28.21亿元，同比下降3.24%。净利润1.84亿元，同 比增长18.50%。 ...

华邦健康（002004）公告，2024年营业收入116.65亿元，同比增长0.60%。归属于上市公司股东的净亏 损2.99亿元，去年同期净利润3.02亿元。基本每股收益-0.1514元/股。公司董事会审议通过的利润分配预 案为不派发现金红利，不送红股，不以资本公积金转增股本。 ...

截至4月11日收盘，转基因概念下跌5.96%，位居概念板块跌幅榜前列，板块内，万向德农跌停，神农 种业、敦煌种业、丰乐种业等跌幅居前，股价上涨的有3只，涨幅居前的有芭田股份、金城医药、科前 生物等，分别上涨5.63%、1.91%、1.07%。 转基因概念资金流出榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002385 | 大北农 | -7.17 | 10.09 | -15703.93 | | 300087 | 荃银高科 | -8.83 | 12.71 | -10991.72 | | 300189 | 神农种业 | -13.04 | 40.95 | -10713.62 | | 000998 | 隆平高科 | -5.46 | 7.89 | -6747.25 | | 002041 | 登海种业 | -6.88 | 6.53 | -5055.55 | | 000713 | 丰乐种业 | -9.02 | 18.03 | -4946.29 | | 600354 | 敦煌种业 | -9.25 | 20. ...